39731-48-1

Basic information

• Product Name: 3,4-dihydroxyxanthone
• Synonyms: 3,4-dihydroxyxanthone
• CAS NO: 39731-48-1
• Molecular Formula: C₁₃H₈O₄
• Molecular Weight: 0
• Mol File: 39731-48-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 419.4°Cat760mmHg
• Flash Point: 168°C
• Appearance: /
• Density: 1.516g/cm³
• Vapor Pressure: 1.25E-07mmHg at 25°C
• Refractive Index: 1.717
• CAS DataBase Reference: 3,4-dihydroxyxanthone(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydroxyxanthone(39731-48-1)
• EPA Substance Registry System: 3,4-dihydroxyxanthone(39731-48-1)

Safety Data

• Hazardous Substances Data: 39731-48-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H8O4/c14-9-6-5-8-11(15)7-3-1-2-4-10(7)17-13(8)12(9)16/h1-6,14,16H

Upstream product

• 5715-02-6 2-acetoxybenzonitrile 
• 87-66-1 2-hydroxyresorcinol 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 1143-72-2 2,3,4-trihydroxybenzophenone 
• 634-36-6 1,2,3-trimethoxybenzene 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 5150-42-5 2,3-dimethoxyphenol 
• 69-72-7 salicylic acid 
• 42204-63-7 2,3,4,2'-tetrahydroxy-benzophenone 
• 1204201-92-2 (2-fluorophenyl)(2,3,4-trihydroxy-phenyl)methanone 
• 79-37-8 oxalyl dichloride 
• 445-29-4 o-fluoro-benzoic acid 
• 579-75-9 2-Methoxybenzoic acid 
• 24061-29-8 3,4-dimethoxyxanthen-9-one 

Downstream Products

• 110597-45-0 (+/-)-(2R,3R)-2,3-dihydro-2-(hydroxymethyl)-3-(4-hydroxy-3-methoxyphenyl)-7H-[1,4]dioxino[5,6-c]xanthen-7-one 
• 110597-42-7 ethyl 2-<9H-(3-benzyloxy-9-oxo)xanthen-4-yl>oxy-3-oxo-3-(4-benzyloxy-3-methoxyphenyl)propionate 
• 110597-44-9 2,3-dihydro-2-ethoxycarbonyl-3-(4-hydroxy-3-methoxyphenyl)-7H-1,4-dioxino-<2,3-c>xanthen-7-one 
• 110597-43-8 ethyl 2-<9H-(3-hydroxy-9-oxo)xanthen-4-yl>oxy-3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propionate 
• 110597-41-6 3-benzyloxy-4-hydroxyxanthone 

Relevant articles and documents

DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions

Four 5,6-dimethylxanthone-4-acetic acid (D) and pyranoxanthone (P) hybrids (D-P-n) were design-synthesized based on multi-target-addressed strategy. D-P-4 was confirmed as the most active agent against HepG-2 cell line growth with an IC50 of 0.216 ± 0.031 μM. Apoptosis analysis indicated different contributions of early/late apoptosis/necrosis to cell death for both monomers, the combination (D + P in 1:1 mol ratio) and D-P-4. They all arrested more cells on S phase. Western Blot implied that D-P-4 regulated p53/MDM2 to a better healthy state. Moreover, it improved Bax/Bcl-2 signaling pathway to increase cancer cell apoptosis. In all cases studied, D-P-4 showed the best activity and synergistic effect. All the evidences support that D-P-4 is a better anti-cancer therapy with multi-target functions.

Synthesis and evaluation of caged Garcinia xanthones

Inspired by the combination of unique structure and potent bioactivities exhibited by several family members of the caged Garcinia xanthones, we developed a synthesis of simplified analogues that maintain the overall caged motif. The caged structure of th

Compound as DMXAA-Pyranoxanthone well as preparation method and application thereof

The invention discloses a DMXAA-Pyranoxanthone heterozygous compound with an anti-tumor effect and a preparation method and application thereof. The DMXAA-Pyranoxanthone heterozygous compound adopts the structural formula shown as a formula I. The preparation method comprises the following steps: preparing DMXAA in three steps, preparing pyranoxanthone in two steps, and combining the DMXAA and the pyranoxanthone into the DMXAA-Pyranoxanthone heterozygous compound in two steps. The DMXAA-Pyranoxanthone heterozygous compound and a DMXAA/pyranoxanthone combined medicine have excellent in-vitro tumor cell proliferation inhibiting activity on breast cancer cells, liver cancer cells, leukemia cells, and can induce apoptosis of tumor cells through multiple targets. The DMXAA-Pyranoxanthone heterozygous compound and the DMXAA/pyranoxanthone combined medicine can be applied to preparation of cancer treating medicines.

* One derivative containing nitrogen and its preparation method and application (by machine translation)

The invention discloses a formula (I) of formula (II) containing nitrogen mouth Shan Tong derivative and its preparation method and application, A new synthesis of this invention containing nitrogen mouth Shan Tong derivatives of the salt and its acid salt, increased solubility, active research indicates part of the compound at the same time with treating and/or preventing diabetes and complications from diabetes mellitus the role of the, can further carry out development research as a model for treating and/or preventing diabetes caused by the complications of diabetes medicine. (by machine translation)